KalVista Pharmaceuticals (NASDAQ: KALV) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare KalVista Pharmaceuticals to similar businesses based on the strength of its dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.
Valuation & Earnings
This table compares KalVista Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|KalVista Pharmaceuticals||$1.50 million||-$18.60 million||N/A|
|KalVista Pharmaceuticals Competitors||$564.12 million||$96.17 million||44.18|
This is a summary of current ratings for KalVista Pharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|KalVista Pharmaceuticals Competitors||141||801||1773||60||2.63|
KalVista Pharmaceuticals currently has a consensus target price of $27.00, indicating a potential upside of 183.91%. As a group, “Biopharmaceuticals” companies have a potential upside of 11.21%. Given KalVista Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than its competitors.
This table compares KalVista Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|KalVista Pharmaceuticals Competitors||-13,496.29%||-110.89%||-28.17%|
Insider and Institutional Ownership
76.1% of KalVista Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.5% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 49.1% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 15.3% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Risk and Volatility
KalVista Pharmaceuticals has a beta of 2.82, indicating that its stock price is 182% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals’ competitors have a beta of 1.12, indicating that their average stock price is 12% more volatile than the S&P 500.
KalVista Pharmaceuticals beats its competitors on 8 of the 12 factors compared.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.